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Introduction.– The natural target of the botulinum neurotoxin type A (BoNT-A)
is the neuro-muscular junction. Botulinum neurotoxins induce flaccid paralysis
by inhibiting synaptic transmission in cholinergic synapses. BoNT-A is known
to block central synapses after muscular injections due to retrograde transport in
animal models. In humans, the question of a possible direct central action of
BoNT-A is still debated. The present study was designed to address whether
BoNT-A modifies the activity of the spinal recurrent inhibitories pathways,
when injected at muscular level.
Patients and methods.– Experiments were performed on 14 post- stroke patients
exhibiting spasticity in ankle plantarflexors, before injection then one month
after BoNT-A. The protocol for the study of heteronymous recurrent inhibition
from soleus to quadriceps motoneurones is based on the pattern of distribution
of recurrent inhibition in human lower limbs. Inhibition was revealed by testing
the influence of PTN stimulation on quadriceps Hoffmann reflex amplitude
(VL).
Results.– One month after BoNT-A, the level of recurrent inhibition was
depressed significantly: average – 45.2  9.2% (P < 0.001). No relationship
was found between the date of stroke and loss of inhibition. Loss of inhibition
was stronger in patients who had not received BoNT-A before the investigation
(P < 0.02) and in patients who had 5–6 injections sites than in patients who had
3–4 injections sites (P < 0.05).
Discussion.– We suggest that catalytically active BoNT-A may act
presynaptically, reducing acetylcholine release in motoneurone recurrent
terminals projecting on Renshaw cells impinging on VL motoneurones.
Recurrent inhibition is normally depressed to assist upright position and stance
phase of walking, partly via the inhibitory corticospinal control on Renshaw
cells, which may contribute to muscle synergy. After stroke, an altered
descending drive may be responsible for the lack in task-dependent modulation
of Renshaw cell activity, that may make muscle synergies less flexible.
The BoNT-A induced depression of recurrent inhibition could thus compensate
for the lack of inhibitory corticospinal control after stroke and contribute to
improve motor synergy in the process of functional recovery of locomotion and
upright position.
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Introduction.– Intrathecal baclofen (ITB) therapy is an effective treatment for
multifocal spasticity. However, this treatment does not always properly handle
spasticity in the upper limbs (UL), or dystonic movements. Recently,
intraventricular baclofen (IVB) therapy has been proposed [1] for the treatment
of intractable spasticity or dystonia. This therapeutic raises some questions at
least about posology and complications of such technique.
Aim.– The aim of this preliminary study was to identify the daily dose of
baclofen infusion, the effects and the complication of IVB therapy.
Method.– Series of five adults and one child with spastic quadriplegia (five with
cerebral palsy, and one after brain traumatic injury). We report the evaluation of
spasticity before/after IVB assessed by the Ashworth scale, postoperative
complications and the mean daily dose of IVB infusion.
Results.– Four subjects were previously treated with ITB which did not allow a
good control of spasticity in their upper limbs. One subject received IVB for
severe dystonia. Two subjects were not implanted with ITB before. No
intraoperative complication was found. Two catheters were repositioned
precisely in the third ventricle due to poor initial efficiency of IVB. One was
explanted due to infection. The result on lower limbs spasticity was as good with
IVB than with ITB. However, there was a greater improvement in spasticity in
UL with IVB compared to ITB. The average daily dose was 420 mg/24 h
compared to the ITB average dose of 400 mg/24 h. Significant control of
dystonic movements was observed.
Conclusion.– The IVB appears to have significantly better efficacy on spasticity
of upper limbs, with a tolerance equal to the ITB delivery. These promising
results require further investigation. This technique seems to be particularly
useful in patients with dystonia or having a spine making lumbar access
difficult.
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Introduction.– Injection sets of botulinum toxin are painful. What is the
part due to the four times of the technique: skin breaking, electrical
stimulation for localization, injection, needle withdrawal? Although clinically
important, this question has been little addressed. This was the objective of this
study.
Method.– Prospective study including 26 patients (16 M/10 W, age
61.4  14years) treated without analgesia by Botox1 or Dysport1 for upper
limb spasticity (5th injection set in average), 9.1 years after a stroke. Pain
intensity was assessed using a verbal scale from 0 to 10, after each of the 4 steps
(skin breaking, electrical stimulation, product injection, withdrawal of the
needle) of every injection. Sensory loss was quantified using Semmes-
Weinstein filaments. Statistics were nonparametric and data expressed as
follows: average [95% LCL and UCL].
Results.– The average number of muscles injected per patient was 3.4 and the
average number of injections per muscle 1.6. Electrical stimulation was the
most painful time (4.4 [3.3–5.4]; P < 0.001), followed by skin breaking (3.1
[2.1–4.1]; P < 0.01). Pain at injection was not negligible (1.6 [0.9–2.3]), greater
than pain accompanying the withdrawal of the needle (0.8 [0.3–1.4]; P < 0.05].
No significant correlation was found between pain intensity and clinical
characteristics of patients, including sensory loss.
Discussion.– This study specifies the nature and intensity of pain during
treatment by botulinum toxin without analgesia of the upper limb spasticity in
adults with stroke. The penetration of the product into the muscle and the
withdrawal of the needle may be painful. Stimulation time is the most
painful, followed by skin breaking. These findings argue for analgesia
associated with an adaptation and a learning of therapeutic techniques in
order to reduce pain.
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